Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854583 | 0.98 | CHKA (0.47) | HRH3PAOXCHKACA2NCF1 | |
| SCHEMBL856567 | 0.98 | CHKA (0.47) | HRH3PAOXCHKACA2NCF1 | |
| SCHEMBL3964262 | 0.92 | CHKA (0.49) | HRH3PAOXCHKACA2NCF1 | |
| SCHEMBL26488666 | 0.92 | PAOX (0.53) | HRH3PAOXSIGMAR1GNAI3GNAO1 | |
| SCHEMBL22564678 | 0.92 | PAOX (0.53) | HRH3PAOXSIGMAR1GNAI3GNAO1 | |
| SCHEMBL3970460 | 0.92 | PAOX (0.53) | HRH3PAOXSIGMAR1GNAI3GNAO1 | |
| SCHEMBL31092072 | 0.92 | PAOX (0.53) | HRH3PAOXSIGMAR1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL20507343 | 0.90 | PAOX (0.52) | PAOXSIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL856408 | 0.89 | SIGMAR1 (0.50) | PAOXSIGMAR1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3677133 | 0.87 | SIGMAR1 (0.48) | PAOXSIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| EP-4480948-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023151635-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2023-08-17 | — | — | WO | disclosed |
| CN-116589445-A | Compound based on quinazoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | CRBN, CLN6, CDR2 | HRH3 4600/4885PAOX 503/4885CHKA 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.